Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy.

[1]  H. Yaegashi,et al.  Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy , 2021, In Vivo.

[2]  M. Aapro,et al.  BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Kazuhiko Yoshida,et al.  Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. , 2020, Japanese journal of clinical oncology.

[4]  G. Duque,et al.  Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers , 2020, Journal of cachexia, sarcopenia and muscle.

[5]  S. Shariat,et al.  Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia , 2019, Prostate Cancer and Prostatic Diseases.

[6]  Liying Zhang,et al.  Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome , 2019, Cancer management and research.

[7]  L. Ferrucci,et al.  Sarcopenia: A Time for Action. An SCWD Position Paper , 2019, Journal of cachexia, sarcopenia and muscle.

[8]  G. Duque,et al.  Effect of Denosumab on Falls, Muscle Strength, and Function in Community‐Dwelling Older Adults , 2019, Journal of the American Geriatrics Society.

[9]  E. Douni,et al.  RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. , 2019, The Journal of clinical investigation.

[10]  D. Power,et al.  Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. , 2019, Nutrition.

[11]  K. Kawahito,et al.  The psoas muscle index as a predictor of long-term survival after cardiac surgery for hemodialysis-dependent patients , 2019, Journal of Artificial Organs.

[12]  C. Cooper,et al.  Sarcopenia: revised European consensus on definition and diagnosis , 2019, Age and ageing.

[13]  F. Saad,et al.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[14]  S. Horie,et al.  Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy , 2018, Prostate international.

[15]  A. Montano‐Loza,et al.  Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis , 2018, Journal of cachexia, sarcopenia and muscle.

[16]  G. Spolverato,et al.  Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers , 2018, Journal of Gastrointestinal Surgery.

[17]  O. Sartor,et al.  Metastatic Prostate Cancer. , 2018, The New England journal of medicine.

[18]  A. Finelli,et al.  Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[19]  C. Cooper,et al.  Epidemiology of sarcopenia and insight into possible therapeutic targets , 2017, Nature Reviews Rheumatology.

[20]  R. Vessella,et al.  Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models , 2017, Clinical Cancer Research.

[21]  B. Griffin,et al.  Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. , 2016, Clinical nutrition ESPEN.

[22]  J. Body,et al.  Targeting bone metastases in prostate cancer: improving clinical outcome , 2015, Nature Reviews Urology.

[23]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[24]  N. Tunariu,et al.  Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer , 2013, British Journal of Cancer.

[25]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[26]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[27]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.